Implications of external price referencing of pharmaceuticals in Middle East countries

Z. Kaló, Ibrahim Alabbadi, Ola Ghaleb Al Ahdab, Maryam Alowayesh, Mahmoud Elmahdawy, Abdulaziz H. Al-Saggabi, Vito Luigi Tanzi, Daoud Al-Badriyeh, Hamad S. Alsultan, Faleh Mohamed Hussain Ali, Gihan H. Elsisi, Kasem S. Akhras, Z. Vokó, Panos Kanavos

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction: External price referencing (EPR) is applied frequently to control pharmaceutical prices. Our objective was to analyse how EPR is used in Middle Eastern (ME) countries and to compare the price corridor for original pharmaceuticals to non-pharmaceutical services not subjected to EPR. Methods: We conducted a survey on EPR regulations and collected prices of 16 patented pharmaceuticals and 14 non-pharmaceutical services in seven Middle Eastern (ME) countries. Maximum and minimum prices of each pharmaceutical and non-pharmaceutical technology were compared to mean prices in the countries studied by using market exchange rates. Influencing factors of pharmaceutical prices were assessed by multivariate linear regression analysis. Results: The average price corridor is narrower for pharmaceuticals (-39.8%; +35.9%) than for outpatient and hospital services (-81.7%; +96.3%). Conclusion: Our analysis revealed the importance of population size and EPR implementation on drug price levels; however, EPR results in higher pharmaceutical prices in lower-income countries compared to non-pharmaceutical services.

Original languageEnglish
Pages (from-to)993-998
Number of pages6
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume15
Issue number6
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Middle East
Pharmaceutical Preparations
Ambulatory Care
Population Density

Keywords

  • cross-national price comparison
  • external reference pricing
  • international society of pharmacoeconomics and outcomes research
  • Middle East countries
  • pharmaceutical pricing
  • price corridor for pharmaceuticals

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy

Cite this

Implications of external price referencing of pharmaceuticals in Middle East countries. / Kaló, Z.; Alabbadi, Ibrahim; Al Ahdab, Ola Ghaleb; Alowayesh, Maryam; Elmahdawy, Mahmoud; Al-Saggabi, Abdulaziz H.; Tanzi, Vito Luigi; Al-Badriyeh, Daoud; Alsultan, Hamad S.; Ali, Faleh Mohamed Hussain; Elsisi, Gihan H.; Akhras, Kasem S.; Vokó, Z.; Kanavos, Panos.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, No. 6, 01.11.2015, p. 993-998.

Research output: Contribution to journalArticle

Kaló, Z, Alabbadi, I, Al Ahdab, OG, Alowayesh, M, Elmahdawy, M, Al-Saggabi, AH, Tanzi, VL, Al-Badriyeh, D, Alsultan, HS, Ali, FMH, Elsisi, GH, Akhras, KS, Vokó, Z & Kanavos, P 2015, 'Implications of external price referencing of pharmaceuticals in Middle East countries', Expert Review of Pharmacoeconomics and Outcomes Research, vol. 15, no. 6, pp. 993-998. https://doi.org/10.1586/14737167.2015.1048227
Kaló, Z. ; Alabbadi, Ibrahim ; Al Ahdab, Ola Ghaleb ; Alowayesh, Maryam ; Elmahdawy, Mahmoud ; Al-Saggabi, Abdulaziz H. ; Tanzi, Vito Luigi ; Al-Badriyeh, Daoud ; Alsultan, Hamad S. ; Ali, Faleh Mohamed Hussain ; Elsisi, Gihan H. ; Akhras, Kasem S. ; Vokó, Z. ; Kanavos, Panos. / Implications of external price referencing of pharmaceuticals in Middle East countries. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2015 ; Vol. 15, No. 6. pp. 993-998.
@article{f8b2d098b55e4c79aa48e829a788dd21,
title = "Implications of external price referencing of pharmaceuticals in Middle East countries",
abstract = "Introduction: External price referencing (EPR) is applied frequently to control pharmaceutical prices. Our objective was to analyse how EPR is used in Middle Eastern (ME) countries and to compare the price corridor for original pharmaceuticals to non-pharmaceutical services not subjected to EPR. Methods: We conducted a survey on EPR regulations and collected prices of 16 patented pharmaceuticals and 14 non-pharmaceutical services in seven Middle Eastern (ME) countries. Maximum and minimum prices of each pharmaceutical and non-pharmaceutical technology were compared to mean prices in the countries studied by using market exchange rates. Influencing factors of pharmaceutical prices were assessed by multivariate linear regression analysis. Results: The average price corridor is narrower for pharmaceuticals (-39.8{\%}; +35.9{\%}) than for outpatient and hospital services (-81.7{\%}; +96.3{\%}). Conclusion: Our analysis revealed the importance of population size and EPR implementation on drug price levels; however, EPR results in higher pharmaceutical prices in lower-income countries compared to non-pharmaceutical services.",
keywords = "cross-national price comparison, external reference pricing, international society of pharmacoeconomics and outcomes research, Middle East countries, pharmaceutical pricing, price corridor for pharmaceuticals",
author = "Z. Kal{\'o} and Ibrahim Alabbadi and {Al Ahdab}, {Ola Ghaleb} and Maryam Alowayesh and Mahmoud Elmahdawy and Al-Saggabi, {Abdulaziz H.} and Tanzi, {Vito Luigi} and Daoud Al-Badriyeh and Alsultan, {Hamad S.} and Ali, {Faleh Mohamed Hussain} and Elsisi, {Gihan H.} and Akhras, {Kasem S.} and Z. Vok{\'o} and Panos Kanavos",
year = "2015",
month = "11",
day = "1",
doi = "10.1586/14737167.2015.1048227",
language = "English",
volume = "15",
pages = "993--998",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Implications of external price referencing of pharmaceuticals in Middle East countries

AU - Kaló, Z.

AU - Alabbadi, Ibrahim

AU - Al Ahdab, Ola Ghaleb

AU - Alowayesh, Maryam

AU - Elmahdawy, Mahmoud

AU - Al-Saggabi, Abdulaziz H.

AU - Tanzi, Vito Luigi

AU - Al-Badriyeh, Daoud

AU - Alsultan, Hamad S.

AU - Ali, Faleh Mohamed Hussain

AU - Elsisi, Gihan H.

AU - Akhras, Kasem S.

AU - Vokó, Z.

AU - Kanavos, Panos

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Introduction: External price referencing (EPR) is applied frequently to control pharmaceutical prices. Our objective was to analyse how EPR is used in Middle Eastern (ME) countries and to compare the price corridor for original pharmaceuticals to non-pharmaceutical services not subjected to EPR. Methods: We conducted a survey on EPR regulations and collected prices of 16 patented pharmaceuticals and 14 non-pharmaceutical services in seven Middle Eastern (ME) countries. Maximum and minimum prices of each pharmaceutical and non-pharmaceutical technology were compared to mean prices in the countries studied by using market exchange rates. Influencing factors of pharmaceutical prices were assessed by multivariate linear regression analysis. Results: The average price corridor is narrower for pharmaceuticals (-39.8%; +35.9%) than for outpatient and hospital services (-81.7%; +96.3%). Conclusion: Our analysis revealed the importance of population size and EPR implementation on drug price levels; however, EPR results in higher pharmaceutical prices in lower-income countries compared to non-pharmaceutical services.

AB - Introduction: External price referencing (EPR) is applied frequently to control pharmaceutical prices. Our objective was to analyse how EPR is used in Middle Eastern (ME) countries and to compare the price corridor for original pharmaceuticals to non-pharmaceutical services not subjected to EPR. Methods: We conducted a survey on EPR regulations and collected prices of 16 patented pharmaceuticals and 14 non-pharmaceutical services in seven Middle Eastern (ME) countries. Maximum and minimum prices of each pharmaceutical and non-pharmaceutical technology were compared to mean prices in the countries studied by using market exchange rates. Influencing factors of pharmaceutical prices were assessed by multivariate linear regression analysis. Results: The average price corridor is narrower for pharmaceuticals (-39.8%; +35.9%) than for outpatient and hospital services (-81.7%; +96.3%). Conclusion: Our analysis revealed the importance of population size and EPR implementation on drug price levels; however, EPR results in higher pharmaceutical prices in lower-income countries compared to non-pharmaceutical services.

KW - cross-national price comparison

KW - external reference pricing

KW - international society of pharmacoeconomics and outcomes research

KW - Middle East countries

KW - pharmaceutical pricing

KW - price corridor for pharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=84948755498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948755498&partnerID=8YFLogxK

U2 - 10.1586/14737167.2015.1048227

DO - 10.1586/14737167.2015.1048227

M3 - Article

VL - 15

SP - 993

EP - 998

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 6

ER -